US Patent

US12268695 — Betulin-containing birch bark extracts and their formulation

Method of Use · Assigned to Amryt Pharmaceuticals Designated Activity Co · Expires 2039-01-04 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using birch bark extracts containing triterpenes, such as betulin, for improving wound healing.

USPTO Abstract

The present disclosure relates to birch bark extracts, methods of producing such extracts, stable pharmaceutical compositions containing such extracts and methods of using of such extracts. The birch bark extracts of the present disclosure contain triterpenes, which are known to improve wound healing.

Drugs covered by this patent

birch-triterpenes (BIRCH TRITERPENES)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3811`	—	birch-triterpenes

Patent Metadata

Patent number: US12268695
Jurisdiction: US
Classification: Method of Use
Expires: 2039-01-04
Drug substance claim: No
Drug product claim: No
Assignee: Amryt Pharmaceuticals Designated Activity Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.